by HER-2 negative breast cancer refers to breast cancer in which the tumor cells do not have an excess of the human epidermal growth factor receptor 2 (HER2) protein. HER-2 negative breast cancer typically accounts for approximately 70-75% of all breast cancer cases globally. Products in this market include chemotherapy drugs such as anthracyclines and taxanes, endocrine therapies such as tamoxifen and aromatase inhibitors as well as targeted therapies. These drugs play a vital role in effectively treating HER-2 negative breast cancer which has overtaken lung cancer as the leading cause of cancer death among women globally.
The Global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 15982.51 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the HER-2 negative breast cancer are Robert Bosch GmbH (Germany), HELLA KGaA (Germany), Continental AG (Germany), Denso Corporation (Japan), Delphi Automotive PLC (U.K.), Autoliv Inc. (Sweden), and Valeo S.A. (France) are the system manufacturers and companies such as Infineon Technologies AG (Germany).
The growing incidences of HER-2 Negative Breast Cancer Cases Market Size globally is a major factor driving the demand for innovative drugs and targeted therapies in this market. According to the WHO, breast cancer is the most common cancer among women with an estimated 2.3 million new cases diagnosed in 2020. Further, approximately 70–75% of breast cancers are considered HER2-negative.
Major market players are focusing efforts on expanding into emerging markets of Asia Pacific, Latin America, and Middle East & Africa through partnerships and strategic collaborations with regional healthcare providers to cater to the growing patient needs in these regions.
Market Key Trends
Growing focus on personalized medicine and targeted therapies for HER-2 negative breast cancer treatment is a key trend in this market. With advancements in genomics and molecular profiling, drugs are being developed that target specific mutations, genes or proteins that fuel cancer growth and survival. For example, drugs such as Palbociclib (Ibrance) which targets CDK 4/6 proteins involved in cancer cell growth. Such targeted therapies are more effective with fewer side effects compared to conventional chemotherapy regimens. This trend will continue to evolve with focus shifting towards precision medicine based treatments customized for individual patients.
Porter’s Analysis
Threat of new entrants: New companies will face high costs for R&D and requirements for regulatory approval.
Bargaining power of buyers: Buyers have some power as they can choose from alternative treatment options.
Bargaining power of suppliers: Suppliers of drug manufacturing have moderate bargaining power as biologics require specialized production facilities.
Threat of new substitutes: Potential substitutes like targeted therapy drugs pose threat depending on their clinical efficacy.
Competitive rivalry: Competition is high among existing immunotherapy and targeted therapy drugs.
Geographical Regions: North America currently holds the largest share of the HER-2 negative breast cancer market in terms of value due to growing prevalence of breast cancer, increasing awareness, and readily available diagnostic facilities.
The Asia Pacific region is poised to grow at the highest CAGR during the forecast period owing to growth opportunities presented by countries like China and India where awareness is increasing and healthcare infrastructure is developing. Rising generics market is also boosting the Asia Pacific market.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
